Patients With High-Risk DLBCL Benefit From Dose-Dense Immunochemotherapy Combined With Early Systemic CNS Prophylaxis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patients With High-Risk DLBCL Benefit From Dose-Dense Immunochemotherapy Combined With Early Systemic CNS Prophylaxis
Blood Adv 2020 May 12;4(9)1906-1915, S Leppä, J Jørgensen, A Tierens, L Meriranta, I Østlie, P de Nully Brown, UM Fagerli, TS Larsen, S Mannisto, L Munksgaard, M Maisenhölder, K Vasala, P Meyer, M Jerkeman, M Björkholm, Ø Fluge, S Jyrkkiö, K Liestøl, E Ralfkiaer, S Spetalen, K Beiske, ML Karjalainen-Lindsberg, H HolteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.